ADVENZYMES

Advanced Enzyme Technologies reported strong FY26 performance, marking a turnaround from FY25 with broad-based growth across all segments. Management expects to maintain double-digit overall growth with steady margins, driven by increased productivity, efficiencies, and strategic R&D investments. A new R&D center in Nashik will be operational in H2 FY27, aiming to triple product development capacity. The company anticipates EU approval for anti-inflammatory products this year, presenting a significant market opportunity. Overall R&D CapEx for the year is projected around INR 130 crores. While acknowledging challenges in the US market and inflationary pressures, management aims to grow globally and will consider capacity expansion in a subsidiary this year.

Advanced Enzyme Technologies Ltd. announced that the audio recording of the conference call held on May 12, 2026, to discuss the Audited Financial Results for the quarter and year ended March 31, 2026, is available on the company's website. The transcript will be uploaded in due course.

Consolidated Revenue ₹2,034 Mn vs ₹1,672 Mn (▲22% YoY), EBITDA ₹632 Mn vs ₹456 Mn (▲39% YoY), PAT ₹453 Mn vs ₹267 Mn (▲69% YoY). EBITDA Margin 31% vs 27% (▲400bps).

Advanced Enzyme Technologies Ltd. board meeting on May 09, 2026, approved FY26 and Q4 FY26 consolidated financial results. A final dividend of ₹1.35 per equity share (67.5%) for FY26 was recommended, subject to AGM approval. The company deferred an interim dividend to preserve capital for strategic initiatives. The board also approved the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors, and appointed Mr. Pradip Bhailal Shah as an Independent Director. Additionally, 49,350 ESOP shares were allotted.

Advanced Enzyme Technologies Ltd. board meeting on May 09, 2026, approved the annual and Q4 FY26 financial results and recommended a final dividend of ₹1.35 per equity share (67.5% on face value of ₹2) for FY 2025-26. The board deferred an interim dividend to preserve capital for future strategic actions. Key governance decisions included the re-appointment of Mr. Mukund Kabra as Whole Time Director, the appointment of Mr. Pradip Shah as an Independent Director, and the re-appointment of MSKA & Associates LLP as Statutory Auditors. The company also approved the allotment of 49,350 equity shares under its ESOP scheme. Auditors issued an unmodified opinion on the financial results.

The Board of Directors approved the Annual Financial Results for FY26 and Q4 FY26, and recommended a final dividend of ₹1.35 per equity share. An interim dividend was deferred to preserve capital for strategic evaluation. The Board also approved the re-appointment of Mr. Mukund Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors, and the appointment of Mr. Pradip Bhailal Shah as an Independent Director. Additionally, 49,350 equity shares were allotted under the ESOP Scheme.

Advanced Enzyme Technologies Ltd.'s board met on May 09, 2026, approving FY26 annual and Q4 financial results. The board recommended a final dividend of ₹1.35 per equity share (67.5%) for FY25-26, while deferring an interim dividend to preserve capital for strategic avenues. Key governance decisions included the re-appointment of Mr. Mukund Kabra as Whole-time Director, appointment of Mr. Pradip Bhailal Shah as an Independent Director, and re-appointment of MSKA & Associates LLP as Statutory Auditors. Additionally, 49,350 equity shares were allotted under ESOPs, increasing the company's paid-up capital.

Advanced Enzyme Technologies Ltd.'s Board Meeting on May 09, 2026, approved FY26 Annual Financial Results with an unmodified audit opinion. A final dividend of ₹1.35 per share (67.5%) was recommended, but an interim dividend was deferred to preserve capital for strategic initiatives. The Board re-appointed Mr. Mukund Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors. Mr. Pradip Shah was appointed as an Independent Director. Additionally, 49,350 equity shares were allotted under an ESOP scheme, increasing the company's paid-up share capital.

The Board of Directors of Advanced Enzyme Technologies Ltd. approved the annual financial results for the year ended March 31, 2026, and recommended a final dividend of ₹1.35 per equity share for FY 2025-26, subject to AGM approval. The Board deferred the declaration of an interim dividend to preserve capital for potential strategic avenues. Key governance decisions included the re-appointment of Mr. Mukund Madhusudan Kabra as Whole Time Director and MSKA & Associates LLP as Statutory Auditors, along with the appointment of Mr. Pradip Bhailal Shah as an Independent Director.

Consolidated Revenue ₹2,033.67Mn vs ₹1,671.79Mn (▲21.65% YoY), EBITDA ₹633.41Mn vs ₹456.02Mn (▲38.90% YoY), PAT ₹452.52Mn vs ₹267.28Mn (▲69.31% YoY). EBITDA Margin 31.15% vs 27.28% (▲387bps). The Board also recommended a final dividend of ₹1.35 per equity share for FY 2025-26.

Advanced Enzyme Technologies Limited announced on May 06, 2026, that CRISIL Ratings Limited has reaffirmed its credit ratings for total bank loan facilities of ₹100 Crore. The Long-Term Rating is reaffirmed at CRISIL A+/Stable, and the Short-Term Rating is reaffirmed at CRISIL A1+.

Advanced Enzyme Technologies Ltd. announced a conference call for analysts and investors to discuss the financial results for the quarter and year ended March 31, 2026. The call is scheduled for Tuesday, May 12, 2026, at 09:00 a.m. (IST) and will be attended by Mr. Mukund Kabra (Whole-time Director) and Mr. Beni Prasad Rauka (Chief Financial Officer).